Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 206

1.

Analysis of cross-reactive antibodies recognizing the fusion loop of envelope protein and correlation with neutralizing antibody titers in Nicaraguan dengue cases.

Lai CY, Williams KL, Wu YC, Knight S, Balmaseda A, Harris E, Wang WK.

PLoS Negl Trop Dis. 2013 Sep 19;7(9):e2451. doi: 10.1371/journal.pntd.0002451. eCollection 2013.

2.

Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans.

Puschnik A, Lau L, Cromwell EA, Balmaseda A, Zompi S, Harris E.

PLoS Negl Trop Dis. 2013 Jun 13;7(6):e2274. doi: 10.1371/journal.pntd.0002274. Print 2013.

4.

High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection.

Tsai WY, Lai CY, Wu YC, Lin HE, Edwards C, Jumnainsong A, Kliks S, Halstead S, Mongkolsapaya J, Screaton GR, Wang WK.

J Virol. 2013 Dec;87(23):12562-75. doi: 10.1128/JVI.00871-13. Epub 2013 Sep 11.

5.

Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones.

Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE Jr.

J Virol. 2014 Nov;88(21):12233-41. doi: 10.1128/JVI.00247-14. Epub 2014 Aug 6.

6.

Dominant cross-reactive B cell response during secondary acute dengue virus infection in humans.

Zompi S, Montoya M, Pohl MO, Balmaseda A, Harris E.

PLoS Negl Trop Dis. 2012;6(3):e1568. doi: 10.1371/journal.pntd.0001568. Epub 2012 Mar 20.

7.

The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein.

Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE Jr.

MBio. 2013 Nov 19;4(6):e00873-13. doi: 10.1128/mBio.00873-13.

8.

Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.

Watanabe S, Chan KW, Wang J, Rivino L, Lok SM, Vasudevan SG.

J Virol. 2015 Jun;89(11):5847-61. doi: 10.1128/JVI.00216-15. Epub 2015 Mar 18.

9.

[Analysis of serum neutralizing antibody response in patients with primary dengue virus type 1 infection].

Hu D, Li J, Wang D, DI B, Qiu L, Wang Y, Ding X, Che X.

Nan Fang Yi Ke Da Xue Xue Bao. 2012 Dec;32(12):1773-6, 1791. Chinese.

10.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

11.

Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies.

Buddhari D, Aldstadt J, Endy TP, Srikiatkhachorn A, Thaisomboonsuk B, Klungthong C, Nisalak A, Khuntirat B, Jarman RG, Fernandez S, Thomas SJ, Scott TW, Rothman AL, Yoon IK.

PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3230. doi: 10.1371/journal.pntd.0003230. eCollection 2014 Oct.

12.

Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II.

Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, King CC, Wu HC, Chang GJ, Wang WK.

J Virol. 2008 Jul;82(13):6631-43. doi: 10.1128/JVI.00316-08. Epub 2008 Apr 30.

13.

B Cell Responses during Secondary Dengue Virus Infection Are Dominated by Highly Cross-Reactive, Memory-Derived Plasmablasts.

Priyamvada L, Cho A, Onlamoon N, Zheng NY, Huang M, Kovalenkov Y, Chokephaibulkit K, Angkasekwinai N, Pattanapanyasat K, Ahmed R, Wilson PC, Wrammert J.

J Virol. 2016 May 27;90(12):5574-85. doi: 10.1128/JVI.03203-15. Print 2016 Jun 15.

14.

Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.

Katzelnick LC, Montoya M, Gresh L, Balmaseda A, Harris E.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):728-33. doi: 10.1073/pnas.1522136113. Epub 2016 Jan 4.

15.

Cross-reactivities between human IgMs and the four serotypes of dengue virus as probed with artificial homodimers of domain-III from the envelope proteins.

Zidane N, Dussart P, Bremand L, Bedouelle H.

BMC Infect Dis. 2013 Jul 1;13:302. doi: 10.1186/1471-2334-13-302.

16.

Anti-dengue virus envelope protein domain III IgG ELISA among infants with primary dengue virus infections.

Libraty DH, Zhang L, Obcena A, Brion JD, Capeding RZ.

Acta Trop. 2015 Feb;142:103-7. doi: 10.1016/j.actatropica.2014.11.009. Epub 2014 Nov 25.

17.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

18.

A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies.

Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE Jr, de Silva AM, Baric RS.

MBio. 2015 Oct 13;6(5):e01461-15. doi: 10.1128/mBio.01461-15.

19.

B-cell responses during primary and secondary dengue virus infections in humans.

Mathew A, West K, Kalayanarooj S, Gibbons RV, Srikiatkhachorn A, Green S, Libraty D, Jaiswal S, Rothman AL.

J Infect Dis. 2011 Nov 15;204(10):1514-22. doi: 10.1093/infdis/jir607. Epub 2011 Sep 19.

20.

Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection.

Sasaki T, Setthapramote C, Kurosu T, Nishimura M, Asai A, Omokoko MD, Pipattanaboon C, Pitaksajjakul P, Limkittikul K, Subchareon A, Chaichana P, Okabayashi T, Hirai I, Leaungwutiwong P, Misaki R, Fujiyama K, Ono K, Okuno Y, Ramasoota P, Ikuta K.

Antiviral Res. 2013 Jun;98(3):423-31. doi: 10.1016/j.antiviral.2013.03.018. Epub 2013 Mar 29.

PMID:
23545366

Supplemental Content

Support Center